Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia.

However, ATP1B1 shows only a trend toward lower expression in CN-AML patients with NPM1 mutation, as well as a slight trend toward higher expression in patients with single or double CEBPA mutation, which is not consistent with the known prognostic role of CEBPA mutations.

also in 4,078 other papers